Analyst Consensus ?
ConsensusHold34 ratings
Bullish1441.2%
Neutral1544.1%
Bearish514.7%
FN2 Earnings Intelligence
ResMed Inc. analyst ratings
ResMed Inc. (RMD) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$251.69Current
$175Low
$247.73Average
$345High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 28, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| RBC Capital | Outperform | Sector Perform | Upgrade | Sep 15, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Aug 31, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 7, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 7, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 15, 2026 |
| Citigroup | Neutral | Buy | Downgrade | Jul 13, 2026 |
| Jefferies | Hold | Hold | Maintain | Jul 10, 2026 |
| Morgan Stanley | Equal Weight | Overweight | Downgrade | Jun 17, 2026 |
| Stifel | Hold | Hold | Maintain | Jan 30, 2026 |
| Baird | Neutral | Outperform | Downgrade | Dec 16, 2025 |
| UBS | Buy | Buy | Maintain | Aug 1, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Apr 24, 2025 |
| Needham | Hold | Hold | Maintain | Jan 31, 2025 |
| B of A Securities | Buy | Buy | Maintain | Sep 26, 2024 |
| Wolfe Research | Underperform | Peer Perform | Downgrade | Sep 18, 2024 |
| Oppenheimer | Perform | Outperform | Downgrade | Jun 25, 2024 |
| CLSA | Buy | Outperform | Maintain | Jan 13, 2022 |
| Macquarie | Outperform | Neutral | Upgrade | Dec 6, 2021 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jul 29, 2019 |
| Deutsche Bank | Buy | Hold | Upgrade | Mar 20, 2019 |
| BMO Capital | Outperform | Market Perform | Upgrade | Dec 10, 2018 |
| Barclays | Underweight | Underweight | Maintain | Oct 27, 2017 |
| Credit Suisse | Neutral | Outperform | Downgrade | Aug 2, 2017 |
| Bank of America | Neutral | Buy | Downgrade | Aug 2, 2017 |
| PiperJaffray | Neutral | Overweight | Downgrade | Apr 27, 2016 |
| BBY | Underperform | Underperform | Maintain | Feb 2, 2015 |
| Northland Securities | Underperform | Market Perform | Downgrade | May 27, 2014 |
| Northland Capital Markets | Underperform | Market Perform | Downgrade | May 27, 2014 |
| William Blair | Market Perform | Outperform | Downgrade | Jan 24, 2014 |
| Shaw Stockbroking | Buy | Buy | Maintain | Sep 20, 2013 |
| S&P Capital IQ | Buy | Buy | Maintain | Feb 26, 2013 |
| CBA | Buy | Hold | Upgrade | Aug 7, 2012 |
| Feltl & Co. | Hold | Hold | Maintain | Aug 6, 2012 |
| Bank oferica | Neutral | Neutral | Maintain | Apr 27, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $251.7. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Mizuho Securities | Anthony Petrone | $240 | $234.6 | -4.6% | Oct 13, 2026 |
| RBC Capital | Craig Wong-Pan | $262 | $222.99 | +4.1% | Sep 15, 2026 |
| KeyBanc | Analyst unavailable | $267 | $240.33 | +6.1% | Aug 31, 2026 |
| Redburn Partners | Analyst unavailable | $230 | $219.98 | -8.6% | Aug 19, 2026 |
| Robert W. Baird | Analyst unavailable | $213 | $212.38 | -15.4% | Aug 7, 2026 |
| KeyBanc | Analyst unavailable | $255 | $223.24 | +1.3% | Aug 7, 2026 |
| UBS | David Low | $300 | $195.97 | +19.2% | Jul 21, 2026 |
| RBC Capital | Analyst unavailable | $234 | $198.57 | -7.0% | Jul 16, 2026 |
| Mizuho Securities | Analyst unavailable | $220 | $193.01 | -12.6% | Jul 15, 2026 |
| Jefferies | Analyst unavailable | $225 | $204.5 | -10.6% | Jul 10, 2026 |
| RBC Capital | Analyst unavailable | $276 | $219.75 | +9.7% | Jul 8, 2026 |
| Wells Fargo | Analyst unavailable | $225 | $219.75 | -10.6% | Jul 8, 2026 |
| KeyBanc | Analyst unavailable | $266 | $188.63 | +5.7% | Jun 22, 2026 |
| Morgan Stanley | David Bailey | $230 | $193.94 | -8.6% | Jun 17, 2026 |
| Robert W. Baird | Analyst unavailable | $225 | $203.87 | -10.6% | May 1, 2026 |
| KeyBanc | Analyst unavailable | $290 | $219.85 | +15.2% | Apr 27, 2026 |
| Evercore ISI | Anthony Petrone | $255 | $228.33 | +1.3% | Apr 13, 2026 |
| RBC Capital | Craig Wong-Pan | $314 | $254.08 | +24.8% | Jan 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $265 | $257.61 | +5.3% | Jan 30, 2026 |
| KeyBanc | Brett Fishbin | $302 | $257.61 | +20.0% | Jan 30, 2026 |
| Robert W. Baird | Analyst unavailable | $281 | $257.61 | +11.6% | Jan 30, 2026 |
| Piper Sandler | Analyst unavailable | $275 | $257.61 | +9.3% | Jan 30, 2026 |
| Stifel Nicolaus | Jonathan Block | $260 | $245.94 | +3.3% | Dec 18, 2025 |
| Robert W. Baird | Analyst unavailable | $275 | $253.07 | +9.3% | Dec 16, 2025 |
| UBS | Marcus Curley | $345 | $251.38 | +37.1% | Dec 12, 2025 |
| Robert W. Baird | Analyst unavailable | $300 | $246.88 | +19.2% | Nov 3, 2025 |
| KeyBanc | Brett Fishbin | $299 | $244.12 | +18.8% | Oct 31, 2025 |
| Morgan Stanley | David Bailey | $305 | $252.26 | +21.2% | Oct 31, 2025 |
| Morgan Stanley | Analyst unavailable | $304 | $271.41 | +20.8% | Oct 21, 2025 |
| Wells Fargo | Analyst unavailable | $280 | $272 | +11.2% | Oct 13, 2025 |
| Morgan Stanley | David Bailey | $286 | $248.14 | +13.6% | May 20, 2025 |
| KeyBanc | Brett Fishbin | $274 | $232.65 | +8.9% | Apr 24, 2025 |
| Mizuho Securities | Anthony Petrone | $265 | $211.49 | +5.3% | Apr 16, 2025 |
| Stifel Nicolaus | Analyst unavailable | $240 | $223.83 | -4.6% | Mar 5, 2025 |
| Piper Sandler | Adam Maeder | $260 | $236.18 | +3.3% | Jan 31, 2025 |
| Stifel Nicolaus | Jonathan Block | $250 | $242.51 | -0.7% | Dec 12, 2024 |
| RBC Capital | Craig Wong-Pan | $224 | $238.95 | -11.0% | Oct 1, 2024 |
| Robert W. Baird | Joe Vruwink | $280 | $246.18 | +11.2% | Sep 23, 2024 |
| Wolfe Research | Mike Polark | $180 | $250.88 | -28.5% | Sep 18, 2024 |
| RBC Capital | Craig Wong-Pan | $187 | $194.27 | -25.7% | Apr 10, 2024 |
| Stifel Nicolaus | Mike Matson | $224 | $198.03 | -11.0% | Apr 1, 2024 |
| Oppenheimer | Suraj Kalia | $175 | $134.65 | -30.5% | Oct 27, 2023 |
| Needham | Mike Matson | $180 | $153.89 | -28.5% | Sep 6, 2023 |
| RBC Capital | Craig Wong-Pan | $244 | $197.57 | -3.1% | Jun 20, 2022 |
| RBC Capital | Analyst unavailable | $233 | $200.81 | -7.4% | Apr 29, 2022 |
| Oppenheimer | Suraj Kalia | $312 | $253.77 | +24.0% | Oct 14, 2021 |
| Morgan Stanley | Sean Laaman | $250 | $271.87 | -0.7% | Aug 4, 2021 |
| Jefferies | Anthony Petrone | $240 | $264.75 | -4.6% | Jul 28, 2021 |
Track every rating change on RMD the moment it posts. Free to start.
Start freeGet the RMD recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.